-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

The ALPHA3 Trial: Harnessing the Potential of Combining Next-Generation "Off-the-Shelf" Investigational CAR T Product with Advanced MRD Testing to Improve Outcomes in First Line LBCL

Sponsor: Foresight Diagnostics
Program: Clinical Trial Showcases
Hematology Disease Topics & Pathways:
Research, Clinical Research, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Measurable Residual Disease
Saturday, December 7, 2024: 3:30 PM-3:45 PM
Room 4 (San Diego Convention Center)
Speakers:
David Kurtz, MD, PhD, Foresight Diagnostics , Sandra Close, PhD, Foresight Diagnostics and John Truesdell, MBA, Foresight Diagnostics
Disclosures:
Close: Foresight Diagnostics: Current Employment.

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only
See more of: Clinical Trial Showcases
<< Previous Session | Next Session >>